

Martina Chirra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8162461/publications.pdf>

Version: 2024-02-01

10
papers

174
citations

1307366

7
h-index

1474057

9
g-index

10
all docs

10
docs citations

10
times ranked

281
citing authors

#	ARTICLE	IF	CITATIONS
1	Telemedicine in Neurological Disorders: Opportunities and Challenges. <i>Telemedicine Journal and E-Health</i> , 2019, 25, 541-550.	1.6	94
2	Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy. <i>Clinical Colorectal Cancer</i> , 2018, 17, 307-312.	1.0	23
3	Paraneoplastic movement disorders: phenomenology, diagnosis, and treatment. <i>European Journal of Internal Medicine</i> , 2019, 67, 14-23.	1.0	11
4	Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 627 T non-metastatic gastric cancer. <i>Surgical Oncology</i> , 2020, 32, 2-7.	0.8	11
5	Skin Cancer May Delay Onset but Not Progression of Parkinson's Disease: A Nested Case-Control Study. <i>Frontiers in Neurology</i> , 2020, 11, 406.	1.1	9
6	An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC). <i>Critical Reviews in Oncology/Hematology</i> , 2020, 149, 102921.	2.0	8
7	Genetic parkinsonisms and cancer: a systematic review and meta-analysis. <i>Reviews in the Neurosciences</i> , 2021, 32, 159-167.	1.4	8
8	Immune Checkpoint Inhibitors Regulate K ⁺ Channel Activity in Cytotoxic T Lymphocytes of Head and Neck Cancer Patients. <i>Frontiers in Pharmacology</i> , 2021, 12, 742862.	1.6	7
9	<p>First-Line Treatment Âwith OlaparibÂfor Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 5479-5489.	0.9	3
10	Androgen receptor splice variant 7 in castration resistant prostate cancer treated with hormonal therapy: what is in the pipeline?. <i>Translational Cancer Research</i> , 2019, 8, S595-S597.	0.4	0